Skip header and navigation

Narrow By

   MORE

7 records – page 1 of 1.

5-Aminosalicylate (5-ASA) for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1483
Available Online
View Pamphlet
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Crohn Disease - drug therapy
Colitis - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Colitis
Abstract
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
Notes
Previous title: 5-Aminosalicylate (5-ASA)
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1483
Less detail

Adalimumab therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35127
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1207
Available Online
View Pamphlet
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (11 p.) : digital, PDF file
Subjects (MeSH)
Adalimumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Adalimumab (Humira) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1207
Less detail

Corticosteroid therapy in inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35480
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1546
Available Online
View Pamphlet
Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Alternate Title
Corticosteroid therapy in IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Prednisone
Subjects (LCSH)
Inflammatory bowel diseases
Prednisone
Specialty
Gastrointestinal System
Medications
Abstract
Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Notes
This pamphlet replaced pamphlet 1139, Prednisone Therapy.
Responsibility
Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
Pamphlet Number
1546
Less detail

Golimumab (Simponi®) for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35651
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1641
Available Online
View Pamphlet
Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (12 p.) : digital, PDF file
Subjects (MeSH)
Golimumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Golimumab (Simponi) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1641
Less detail

Infliximab therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams34944
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1140
Available Online
View Pamphlet
Your health care provider feels that treatment with infliximab may help you to manage your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (12 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Infliximab
Subjects (LCSH)
Inflammatory bowel diseases
Infliximab
Abstract
Your health care provider feels that treatment with infliximab may help you to manage your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Infliximab (Remicade) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1140
Less detail

Methotrexate (MTX) therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams34942
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1138
Available Online
View Pamphlet
Your health care provider feels that treatment with methotrexate (meth-oh-TREX-ate) might help your Crohn’s disease or ulcerative colitis. These are both types of inflammatory bowel disease (IBD). This pamphlet explains what methotrexate (MTX) is, how well it works, side effects of MTX, who should not take MTX, and precautions. Instructions for injecting MTX are given.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (13 p.) : digital, PDF file
Subjects (MeSH)
Methotrexate
Crohn's disease
Inflammatory Bowel Diseases
Immunosuppressive Agents
Subjects (LCSH)
Crohn's disease
Methotrexate
Immunosuppressive agents
Inflammatory bowel diseases
Specialty
Gastrointestinal System
Medications
Abstract
Your health care provider feels that treatment with methotrexate (meth-oh-TREX-ate) might help your Crohn’s disease or ulcerative colitis. These are both types of inflammatory bowel disease (IBD). This pamphlet explains what methotrexate (MTX) is, how well it works, side effects of MTX, who should not take MTX, and precautions. Instructions for injecting MTX are given.
Responsibility
Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
Pamphlet Number
1138
Less detail

Ulcerative proctitis

https://libcat.nshealth.ca/en/permalink/chpams35311
Nova Scotia Health Authority. GI Clinic. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1422
Available Online
View Pamphlet
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. GI Clinic
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (4 p.) : digital, PDF file
Subjects (MeSH)
Colitis, Ulcerative
Inflammatory Bowel Diseases
Subjects (LCSH)
Ulcerative colitis
Inflammatory bowel diseases
Abstract
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
Responsibility
Prepared by: GI Clinic
Pamphlet Number
1422
Less detail

7 records – page 1 of 1.